Interferon-α in Malignant and Viral Diseases: A Review

Drugs

Volumn 45, Issue 2, 1993, Pages 177-211

  Dorr, Robert T ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTOCHROME P450; ENDONUCLEASE; MEMBRANE ANTIGEN; SYNTHETASE; THEOPHYLLINE;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CONDYLOMA ACUMINATUM; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; HAIRY CELL LEUKEMIA; HEPATITIS B; HEPATITIS C VIRUS; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; KILLER CELL; MELANOMA; MYELOID LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW; VIRUS INFECTION;

DRUG THERAPY, COMBINATION; HEPATITIS B; HEPATITIS C; HUMAN; INTERFERON-ALPHA; NEOPLASMS; VIRUS DISEASES;

HEPATITIS C VIRUS;

EID: 0027471685     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199345020-00003     Document Type: Review

References (258)

1. Combination of interferon, carboxamide (DTIC) and cimetidine for advanced malignant melanoma
2. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer
3. High doses of natural α-interferon (α-IFN) in the treatment of multiple myeloma — a pilot study from the Myeloma Group of Central Sweden (MGCS)
4. 1-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration
5. Transfusion-associated non-A, non-B hepatitis: the first decade
6. Neutralizing antibodies to interferon-α: relative frequency in patients treated with different interferon preparations
7. Treatment of chronic non-A, non-B hepatitis with human beta-interferon
8. Acute interstitial nephritis with the nephrotic syndrome following recombinant leukocyte A interferon therapy for mycosis fungoides
9. Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumour model system
10. Epidemiology of hepatocellular carcinoma
11. Intraperitoneal recombinant α-interferon for ‘salvage’ immunotherapy in Stage III epithelial ovarian cancer. A Gynecologic Oncology Group study
12. Antitumour activity of new anthracycline analogues in combination with interferon alfa
13. Interferon alpha 2 in treatment of chronic granulocytic leukemia
14. Treatment of hairy cell leukemia with recombinant alfa-2-interferon
15. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa 2a
16. Action of interferon-alpha on hairy cell leukemia: expression of specific receptors and (2′-5′) oligo (A) synthetase in tumour cells from sensitive and resistant patients
17. Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumour cells
18. Involvement of the kidney in catabolism of human leukocyte interferon
19. Human leukocyte interferon: potent endorphin-like opioid activity
20. Common pathways of interferon and hormonal action
21. The lymphatic route. 1. Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma
22. Renal filtration, absorption and catabolism of human alpha interferon
23. The kidney is the main site of interferon catabolism
24. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines
25. Effect of combinations of recombinant interferon alpha and interleukin-2 on tumor metastases and cytotoxic cell function
26. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas
27. Phase II study of interferon alfa-2α, recombinant (Roferon-A) in metastatic renal cell carcinoma
28. Human leukocyte interferon production, purification, and animal experiments
29. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
30. Cervical intraepithelial neoplasia treated by perilesional injection of interferon
31. Levamisole/fluorouracil. A review of their pharmacology and adjuvant therapeutic use in colorectal cancer
32. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies
33. Alpha-2 interferon/melphalan/ prednisone in previously untreated patients with multiple myeloma: a phase I-II trial
34. Randomized trial comparing melphalan-prednisone with or without recombinant alfa 2 interferon (rα2 IFN) in multiple myeloma
35. Interferon down-regulates the male-specific cytochrome P450IIIA2 in rats
36. Interferon suppresses the isoform-specific activities of hepatic cytochrome P450 in female rats
37. Recombinant leukocyte A interferon (rIFN-alpha A) in the treatment of disseminated malignant melanoma: analysis of complete and long-term responding patients
38. Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma
39. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma
40. Phase II study of leukocyte A interferon (IFN Alfa a) plus cimetidine in disseminated malignant melanoma (DMM)
41. A phase I trial of recombinant interferon-alpha and alpha-difluoromethylornithine in metastatic melanoma
42. Hairy cells possess more interferon receptors than other lymphoid cell types
43. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
44. Clinical and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi’s sarcoma
45. A phase I trial of recombinant alpha-2a interferon (Roferon-A) with weekly cisplatinum
46. Recombinant inteferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
47. Deletions of interferon genes in acute lymphoblastic leukemia
48. 1 -interferon genes in human leukemia and derived cell lines
49. Death halts interferon trials in France
50. Effect of interferon, interleukin-2 and tumor necrosis factor on myocardial cell viability and doxorubicin cardiotoxicity in vitro
51. Clinical phase II trial of recombinant DNA interferon (interferon alfa 2b) in patients with metastatic malignant melanoma
52. Inhibitory effects of interferon on mouse megakaryocytic progenitor cells in culture
53. Interferon alfa-2b-cyclophosphamide combination studies: in vitro and phase I-II clinical results
54. Systemic interferon alpha treatment of human condylomata acuminata
55. Interferon and spontaneous cytotoxicity: II. Studies in patients receiving exogenous leukocyte interferon
56. Recombinant leukocyte a interferon (γIFN-α) in renal cell cancer. Abstract
57. Interferon in the treatment of malignant melanoma. Results of clinical studies
58. Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon
59. Parameters of interferon action: I. Immunological effects of whole cell leukocyte interferon in phase I/II trials
60. Interferon therapy for condylomata acuminata
61. Phase II trial of α (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum
62. A phase I study of recombinant human interferons alfa-2a or human lympho-blastoid interferon alf n-1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma
63. Metastatiac renal cancer treated with interleukin-2 and lymphokine-activated killer cells
64. Hairy cell leukemia: clinical presentation and follow-up of 211 patients
65. Metastatic malignant melanoma: regression induced by combined treatment with interferon [huIFN-alpha(le)] and cimetidine
66. Effect of alpha-interferon on the immune system of patients with hairy cell leukemia
67. A prospective randomised trial of alpha 2B-interferon/gamma interferon or the combination in advanced metastatic renal cell carcinoma
68. Interferon therapy of non-Hodgkin’s lymphoma
69. Treatment of advanced non-Hodgkin’s lymphoma with recombinant leukocyte A interferon
70. Is interferon with or without vinblastine the ‘treatment of choice’ in metastatic renal cell carcinoma? The Norwegian Radium Hospital’s experience 1983–1986
71. Interferon alpha 2a for treatment of age-related macular degeneration
72. Chronic lymphocytic leukemia: recent advances in biology and treatment
73. Intralesional administration of large doses of human leukocyte interferon for the treatment of condylomata acuminata
74. Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon
75. Interferon in the treatment of persistent viral warts
76. Alpha-interferon therapy for essential thrombocythaemia
77. Effects of γ-interferon on the endocrine system: results from a phase I study
78. Interferon therapy in cancer: from imaginon to interferon
79. Sequential evaluation of alpha 2b interferon treatment in 128 patients with hairy cell leukemia
80. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients
81. Treatment of basal cell carcinoma with intralesional interferon
82. Modulation of the expression of major histocompatibility antigens on splenic hairy cells — differential effect upon in vitro treatment with alpha-2b interferon, gamma-interferon, and interleukin-2
83. Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome
84. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome
85. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma
86. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon
87. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma
88. Impaired in vitro interferon, blastogenic and natural killer cell responses to viral stimulation in acquired immunodeficiency syndrome
89. Alpha interferon (IFN) induces cytogenetic remissions in patients who relapse with chronic myelogenous leukemia (CML) after allogenic bone marrow transplantation (BMT)
90. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report
91. Randomized, controlled trial of recombinant human α-interferon in patients with chronic hepatitis B
92. Human interferon alpha in malignant lymphoma and Hodgkin’s disease
93. Surface antigens of melanoma and melanocytes
94. Current status of the therapy of advanced renal carcinoma
95. In vivo antitumor activity of multiple injections of recombinant interleukin-2 alone and in combination with three different types of recombinant interferon on various syngeneic murine tumors
96. Interferon response in B-cell prolymphocytic leukemia
97. Antibodies in patients with hairy-cell leukemia receiving alpha-2b interferon
98. Efficacy of 2’-deoxycoformycin in hairy-cell leukemia: a study of the National Cancer Institute of Canada Clinical Trials Group
99. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A®) in cancer patients
100. Interferons modulate the expression of hormone receptors on the surface of murine melanoma cells
101. Treatment of advanced stages of Philadelphia-chromosome (Ph)-positive chronic myelogenous leukemia (CML) with alpha interferon (IFN-A) and low-dose cytosine arabinoside (ara-C)
102. Therapy of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia with initial intensive chemotherapy (DOAP) followed by maintenance with human leukocyte alpha interferon
103. High doses of cyclophosphamide, BCNU and etoposide (CBV) induce cytogenetic responses in most patients with advanced stages of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML)
104. Idiopathisches multiples Pigment-Sarkom der Haut
105. Potential applications of the interferons in oncology: lessions drawn from studies of human melanoma
106. Cutaneous melanoma
107. Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers
108. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
109. Non-A, non-B post transfusion hepatitis — a decade later
110. Combined zidovudine and interferon-α therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS)
111. Pentostatin in the treatment of advanced hairy cell leukemia
112. Renal cell carcinoma: treatment with recombinant interleukin 2 (rIL-2) plus beta interferon (IFN-3)
113. Treatment of epidemic Kaposi’s sarcoma with a combination of interferon alpha 2b and etoposide
114. AIDS and Kaposi’s sarcoma: interferons in pathogenesis and treatment
115. The role of interferon in the therapy of epidemic Kaposi’s sarcoma
116. Kaposi’s sarcoma
117. Treatment of advanced renal cell cancer (RCC) with recombinant leukocyte A interferon (rIFN-αA). Absract
118. Interferon-α with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
119. Preliminary observations on the effect on recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma
120. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
121. Recombinant γ interferon induces hypoertriglyceridemia and inhibits post-heparin lipase activity in cancer patients
122. Interferons-α, β, γ basic principles and preclinical studies
123. Other tumors
124. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi’s sarcoma
125. Antiretroviral effects of interferon-α in AIDS-associated Kaposi’s sarcoma
126. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil
127. Interferon α-2b in the treatment of Philadelphia negative chronic myeloproliferative disorders with excessive thrombocytosis
128. Alfa-2b interferon in the treatment of Hodgkin’s disease and non-Hodgkin’s lymphoma
129. Concomitant administration of recombinant human interleukin-2 and recombinant interferon α-2A in cancer patients: a phase I study
130. Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-α in vitro associated with severe opportunistic infections
131. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders
132. Treatment of chronic myeloid leukemia (CML) using alfa-interferon (IFN), and low dose cytosine arabinoside (ara-C)
133. Modulation by interferons of HLA antigen, high molecular weight melanoma-associated antigen, and intercellular adhesion molecule I expression by cultured melanoma cells with different metastatic potential
134. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy
135. Therapy for condyloma acuminatum: a review
136. Phase I-II study of recombinant interleukin-α2A plus recombinant interferon-α2a in renal cell carcinoma
137. Effects or recombinant interferon-α2 treatment upon lipid concentrations and lipoprotein composition
138. Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN) therapy
139. Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC
140. Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule
141. Treatment of multiple myeloma with natural alpha interferon
142. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation
143. Randomized trial of recombinant α2b-interferon with or without indomethacin in patients with metastatic malignant melanoma
144. Clinical variants and staging of Kaposi’s sarcoma
145. Treatment of dysplasia of the cervical epithelium with an interferon gel
146. Diversity in inhibitory effects of IFN-gamma and IFN-alpha A on the induced DNA synthesis of a hairy cell leukemia B lymphocyte clone reflects the nature of the activating ligand
147. Interferon: clinical applications
148. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia
149. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties
150. 2 and cimetidine in patients with advanced malignant melanoma
151. Renal cell carcinoma
152. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration
153. Combination effects of human recombinant inteferon (alpha-2-arg, gamma) and cytotoxic agents on colony formation of human melanoma and hypernephroma cell lines
154. Intraperitoneal rα2-interferon (IFN) alternating with cis-platin (DDP) as salvage therapy for minimal residual disease ovarian cancer. Abstract
155. Minimal activity of recombinant clone A interferon in metastatic colon cancer
156. Therapy of renal cancer with low (LD), intermediate (ID), and high (HD) dose regimens of human lymphoblastoid interferon (HBLI; Wellferon®). Absract
157. Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a
158. Treatment of chronic myelogenous leukemia with recombinant interferon alpha (IFN-α2b)
159. Recombinant leukocyte α-interferon in advanced ovarian carcinoma
160. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity
161. Treatment of multiple myeloma with recombinant interferon alfa-2a
162. α2) in multiple myeloma: 3-year follow-up. Abstract
163. A phase II trial of interferon alpha2 (rIFNa2) in the treatment of resistant multiple myeloma (MM)
164. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma
165. Cost-benefit analysis of interferon alfa-2b in the treatment of hairy cell leukemia
166. Individual and combined tumoricidal effects of dexamethasone and interferons on human leukocyte cell lines
167. Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report
168. Treatment of chronic non-A, non-B hepatitis with acyclovir pilot study
169. Effects of three recombinant human leukocyte interferons on drug metabolism in mice
170. Renal cell cancer: natural history and results of treatment
171. Effects of interferon-alpha on human warts
172. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
173. Cloning and expression of human interferons in microorganisms
174. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial
175. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
176. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study
177. A prospective multicenter trial with human recombinant alpha-2c-interferon in hairy cell leukemia before and after splenectomy
178. Treatment of multiple myeloma with recombinant α-interferon
179. Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma
180. Treatment of hairy cell leukemia with recombinant alpha interferon
181. Alpha interferons in hairy cell leukemia: a five year follow-up of 100 patients
182. Mid-term observations on the efficacy of alpha-interferon in hairy cell leukemia and status of the interferon system of patients in remission
183. Alpha interferon for induction of remission in hairy-cell leukemia
184. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma
185. Clinical toxicity of interferons in cancer patients: a review
186. Pharmacokinetics of INF α-2b in healthy volunteers
187. Human interferons inhibit experimental metastases of a human melanoma cell line in nude mice
188. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia
189. Relapse after interferon alfa-2b therapy for hairy cell leukemia. Analysis of prognostic variables
190. Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon
191. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis
192. A phase I trial of recombinant interleukin-2 combined with recombinant interferon-gamma in patients with cancer
193. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2
194. Central nervous system toxicity of interferon
195. Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation?
196. The effect of 7-interferon on MHC antigens
197. Synergistic antiproliferative activity of leukocyte interferon in combination with α-difluoromethylornithine against human cells in culture
198. In vivo sensitivity and resistance of chronic myelogenous leukemia cells to α-interferon: correlation with receptor binding and induction of 2′,5′-oligoadenylate synthetase
199. 2-interferon in the treatment of B chronic lymphocytic leukemia in early stages
200. Recombinant human interferon α A/D (F Hu IFN-αA/D) enhances the antiretroviral effect of 3′arido-3′-deoxythymidine (AZT) in mice
201. Kaposi’s sarcoma: a review and recent developments
202. Characterization of the indirect antitumor effect of gamma-interferon using ascites-associated macrophages in a human tumor clonogenic assay
203. Effects of cloned human leukocyte interferons in the human tumor stem cell assay
204. In vitro induction of proteins by alpha-interferon in hairy cell leukemia
205. Phase I study of α2-interferon plus doxorubicin in patients with solid tumors
206. Intravesical treatment of superficial bladder carcinoma with interferons
207. Treatment of metastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant alpha A (IFN, Hoffman-La Roche)
208. Influence of interferon α 2b (IFN) ± leucovorin (LV) on pharmacokinetics (PK) of 5-fluorouracil
209. Effect of injections of small doses of human fibroblast interferon into genital warts: a pilot study
210. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma
211. Combination chemotherapy and α-interferori in the treatment of Kaposi’s sarcoma associated with acquired immune deficiency syndrome
212. Effects of interferon-γ on the activation of human T lymphocytes
213. A phase II trial of high-dose intravenous interferon α-2 in advanced colorectal cancer
214. Cancer Statistics 1990
215. Interferon-mediated depression of cyto-chrome P-450-dependent drug biotransformation
216. Human recombinant interferon-alpha-2 in the treatment of patients with hairy cell Jeukemia
217. Neurologic effects of recombinant human interferon
218. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor
219. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-α2a
220. Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration
221. Additional indications for interferon therapy: basal cell carcinoma, carcinoid, and chronic active hepatitis
222. Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha plus cimetidine in disseminated malignant melanoma
223. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies
224. Effects of short-term corticosteroid therapy in patients with chronic non-A, non-B hepatitis (NANB)
225. Recombinant alpha-interferon for progressive hairy cell leukemia: a study in previously untreated splenectomized patients
226. Chronic myelogenous leukemia and myeloproliferative disorders
227. (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia
228. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia
229. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia
230. Clinical and laboratory changes induced by alpha interferon in chronic lymphocytic leukemia — a pilot study
231. Treatment of metastatic renal cell carcinoma. Recent results
232. Alpha-interferon in superficial bladder cancer
233. Effect of interferon on concentrations of cyclic nucleotides in cultured cells
234. Phase II study of alpha interferon on renal cell carcinoma: summary of three collaboratorive trials
235. Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris
236. Treatment of Kaposi’s sarcoma with interferon alfa-2b (Intron A®)
237. Progressive metastatic renal cell carcinoma controlled by continuous 5-fluoro-2-deoxyuridine infusion
238. Intralesional interferon-alpha therapy in advanced malignant melanoma
239. Immunogenicity of different types of interferons in the treatment of hairy-cell leukemia
240. Therapy with 5-fluorouracil and recombinant interferon-alpha in refractory gastrointestinal malignancies. Abstract
241. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma
242. Phase I study of the combination of alpha-2 interferon and cisplatinum
243. Immunotherapy of a murine tumor with interleukin-2; increased sensitivity after MHC class I gene transfection
244. Survival in chronic hepatitis B: an analysis of 379 patients
245. Interferon in the treatment of ovarian cancer
246. Interferon-α-n 1 in children with recurrent acute lymphocytic leukemia: a phase I study of pharmacokinetics and tolerance
247. Intraperitoneal human r-IFN 2αb in patients with stage III minimal residual ovarian cancer. Abstract
248. Intravesical interferon alfa in the treatment of superficial bladder cancer
249. Randomized trial of high vs low dose intravesical interferon alpha 2B treatment of bladder carcinoma in situ. Abstract
250. Inhibition of theophylline metabolism by interferon
251. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
252. Continuous intravenous infusion pharmacokinetics of interferon to patients with leukemia
253. Effects of prednisone, aspirin, and acetaminophen on an in vivo biologic response to interferon in human
254. The U.K. experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases